A Phase I Study of Evaluating Pharmacokinetics, Safety and Preliminary Efficacy Between Treatment with Endostatin 4 Hours Intravenous Infusion and 72 Hours or 168 Hours Intravenous Pump Infusion in Patients with Advanced Non-Small Cell Lung Cancer